Overexpression of soluble human thymosin alpha 1 in Escherichia coli

被引:12
作者
Chen, PF
Zhang, HY
Fu, GF
Xu, GX
Hou, YY [1 ]
机构
[1] Nanjing Univ, Sch Med, Nanjing 210093, Peoples R China
[2] Nanjing Univ, Sch Life Sci, Nanjing 210093, Peoples R China
关键词
human thymosin alpha 1; Escherichia coli; fusion expression; Ni2+ affinity chromatography;
D O I
10.1111/j.1745-7270.2005.00014.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthesized gene of human thymosin alpha 1 (Talpha(1)) was inserted into pET-28a, pET-9c, pThioHis B, pGEX-2T or pBV222 and then inductively expressed in strains of Escherichia coli. Among the five expression systems, the BL21/pET-28a system provides the highest expression level of fusion protein in a soluble form, which is up to 70% of total expressed bacterial proteins as visualized by sodium dodecyl sulfate-polyacrylarnide gel electrophoresis (SDS-PAGE). The resulting fusion protein purified through nickel affinity chromatography accounts for 2.53% of the wet bacterial pellet weight and reaches 94.5% purity by SDS-PAGE. These results indicate the potential of this expression system for high-throughput production of recombinant Talpha1.
引用
收藏
页码:147 / 151
页数:5
相关论文
共 29 条
[1]   Thymosin alpha-1 [J].
Ancell, CD ;
Phipps, J ;
Young, L .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (10) :879-888
[2]   Thymosin alpha(1) antagonizes dexamethasone and CD3-induced apoptosis of CD4(+)CD8(+) thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways [J].
Baumann, CA ;
Badamchian, M ;
Goldstein, AL .
MECHANISMS OF AGEING AND DEVELOPMENT, 1997, 94 (1-3) :85-101
[3]   Thymosin α1 application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice [J].
Beuth, J ;
Schierholz, JM ;
Mayer, G .
CANCER LETTERS, 2000, 159 (01) :9-13
[4]  
Bianco-Batlles D, 2001, CELL MOL BIOL, V47, P157
[5]  
Billich Andreas, 2002, Curr Opin Investig Drugs, V3, P698
[6]   Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer [J].
Garaci, E ;
Pica, F ;
Sinibaldi-Vallebona, P ;
Pierimarchi, P ;
Mastino, A ;
Matteucci, C ;
Rasi, G .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (08) :1145-1150
[7]   Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application [J].
Garaci, E ;
Pica, F ;
Rasi, G ;
Favalli, C .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 2000, 22 (12) :1067-1076
[8]  
Giuliani C, 2000, EUR J IMMUNOL, V30, P778, DOI 10.1002/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO
[9]  
2-I
[10]   THYMOSIN-ALPHA-1 - ISOLATION AND SEQUENCE-ANALYSIS OF AN IMMUNOLOGICALLY ACTIVE THYMIC POLYPEPTIDE [J].
GOLDSTEIN, AL ;
LOW, TLK ;
MCADOO, M ;
MCCLURE, J ;
THURMAN, GB ;
ROSSIO, J ;
LAI, CY ;
CHANG, D ;
WANG, SS ;
HARVEY, C ;
RAMEL, AH ;
MEIENHOFER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (02) :725-729